Is Our Data Any Good? | GenomeWeb

Is Our Data Any Good?

Premium

We are usually so excited about our projects that as soon as we get data from a new experiment, we can't wait to analyze it. We want to find out as soon as possible whether it supports our hypothesis or which genes play a role in our favorite process. It's not until the answer is unexpected or a "maybe" that we generally start to question the quality of our analytical inputs. But as we get a bit more experienced and more systematic, we're trying to make quality control preliminary steps for analysis rather than just part of the post--mortem examination.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.